Nelivaptan

From Self-sufficiency
Jump to: navigation, search
Nelivaptan
150px
Systematic (IUPAC) name
(2S,4R)-1-[(3R)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-met​hoxyphenyl)-2-oxo-indolin-3-yl]-4-hydroxy-N,N-dimethyl-pyrrolidin​e-2-carboxamide
Clinical data
Routes of
administration		 Oral
Identifiers
CAS Number 439687-69-1
ATC code none
PubChem CID 9895468
ChemSpider 8071134
Chemical data
Formula C30H32ClN3O8S
Molar mass 630.11 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Nelivaptan (INN[1]), codenamed SSR-149,415, is a selective and orally active non-peptide vasopressin receptor antagonist selective for the V1b subtype.[2] The drug had entered clinical trials for treatment of anxiety and depression.[3] In July of 2008, Sanofi-Aventis announced that further development of this drug had been halted.[4]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links


Hypothalamic
Agonists: Lanreotide · Octreotide
Anterior pituitary
Agonists: Thyrotropin
Posterior pituitary
Agonists: Carbetocin · Demoxytocin
Antagonists: Atosiban


45px This hormonal preparation article is a stub. You can help ssf by expanding it.
  1. ↑ World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98" (PDF). WHO Drug Information. 21 (4): 341. 
  2. ↑ Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002). "Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders". Proc. Natl. Acad. Sci. U.S.A. 99 (9): 6370–5. doi:10.1073/pnas.092012099. PMC 122955 Freely accessible. PMID 11959912. 
  3. ↑ Serradeil-Le Gal C, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A (2005). "An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders". CNS drug reviews. 11 (1): 53–68. PMID 15867952. 
  4. ↑ "Second-quarter 2008 results" (PDF). Press Release. Sanofi-Aventis. 2008-07-31. Retrieved 2009-06-10. It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist). 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Nelivaptan&oldid=23285"